ENDRA Life Sciences Future Growth
Future criteria checks 2/6
ENDRA Life Sciences's earnings are forecast to decline at 16.8% per annum while its annual revenue is expected to grow at 256.9% per year. EPS is expected to grow by 11% per annum.
Key information
-16.8%
Earnings growth rate
11.0%
EPS growth rate
| Medical Equipment earnings growth | 16.8% |
| Revenue growth rate | 256.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Dec 2024 |
Recent future growth updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08
We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer
Jun 15ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
Jan 13ENDRA Life Sciences renews GE Healthcare collaboration agreement
Dec 21Endra Life prices $5M-share offering
Dec 16Endra Life Sciences EPS beats by $0.02
Nov 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 0 | -11 | N/A | -11 | 1 |
| 12/31/2024 | N/A | -10 | N/A | -8 | 1 |
| 9/30/2024 | N/A | -9 | -8 | -8 | N/A |
| 6/30/2024 | N/A | -10 | -9 | -9 | N/A |
| 3/31/2024 | N/A | -10 | -9 | -9 | N/A |
| 12/31/2023 | N/A | -10 | -10 | -10 | N/A |
| 9/30/2023 | N/A | -12 | -11 | -10 | N/A |
| 6/30/2023 | N/A | -12 | -11 | -11 | N/A |
| 3/31/2023 | N/A | -13 | -12 | -12 | N/A |
| 12/31/2022 | N/A | -13 | -13 | -13 | N/A |
| 9/30/2022 | N/A | -13 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -12 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -12 | -11 | -11 | N/A |
| 12/31/2021 | N/A | -11 | -11 | -11 | N/A |
| 9/30/2021 | N/A | -10 | -11 | -11 | N/A |
| 6/30/2021 | N/A | -11 | -10 | -10 | N/A |
| 3/31/2021 | N/A | -11 | -11 | -11 | N/A |
| 12/31/2020 | N/A | -12 | -11 | -11 | N/A |
| 9/30/2020 | N/A | -19 | -11 | -11 | N/A |
| 6/30/2020 | N/A | -19 | -11 | -11 | N/A |
| 3/31/2020 | N/A | -18 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -18 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -11 | -9 | -9 | N/A |
| 6/30/2019 | N/A | -10 | -8 | -8 | N/A |
| 3/31/2019 | N/A | -10 | -8 | -8 | N/A |
| 12/31/2018 | 0 | -10 | -8 | -8 | N/A |
| 9/30/2018 | 0 | -10 | -7 | -7 | N/A |
| 6/30/2018 | 0 | -8 | N/A | -6 | N/A |
| 3/31/2018 | 0 | -7 | N/A | -6 | N/A |
| 12/31/2017 | 0 | -5 | N/A | -3 | N/A |
| 9/30/2017 | 1 | -4 | N/A | -2 | N/A |
| 6/30/2017 | 1 | -4 | N/A | -2 | N/A |
| 3/31/2017 | 1 | -3 | N/A | -1 | N/A |
| 12/31/2016 | 1 | -3 | N/A | -1 | N/A |
| 9/30/2016 | 0 | -3 | N/A | -1 | N/A |
| 6/30/2016 | 1 | -2 | N/A | -1 | N/A |
| 3/31/2016 | 1 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 1 | -2 | N/A | -1 | N/A |
| 12/31/2014 | 1 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NDRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NDRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NDRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NDRA's revenue (256.9% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: NDRA's revenue (256.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NDRA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 23:25 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ENDRA Life Sciences Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Kyle Bauser | Colliers Securities |